Roche sends experimental CNS drugs to Newleos, a new biotech backed with $93.5M
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is alive and well. Led by Goldman ...
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is alive and well.
Led by Goldman ...
